NRG-GI011, A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)
Lay Description
NRG-GI011 (LAP100) is a Phase III randomized trial assessing the addition of dose-escalated radiotherapy to chemotherapy in LAPC.
Category
- Cancers and Other Neoplasms
- IRB Number
- STUDY00001932
- NCT Number
- NCT06958328
Eligibility
- Eligible Ages
- 18 - 99
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
Exclusion Criteria
Study Design
Arm Groups
Study Contact
Frances Crawford
210-450-5037
crawfordf1@uthscsa.edu
Myrna Montenegro
210-450-5954
montenegro@uthscsa.edu
Kathleen Rodriguez
210-450-1365
rodriguezk3@uthscsa.edu
Benjamin Schleif
210-450-1366
schleifb@uthscsa.edu
Morgan Seekatz
210-450-1133
seekatz@uthscsa.edu
mccsolidtumor@uthscsa.edu
Principal Investigator
Amy Le